C R Bard Inc (NYSE:BCR) has earned an average rating of “Hold” from the eleven analysts that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and one has given a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $332.00.

Several analysts have recently commented on BCR shares. Zacks Investment Research raised C R Bard from a “hold” rating to a “buy” rating and set a $372.00 price target for the company in a report on Tuesday, December 26th. Barclays raised their price objective on C R Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a research note on Monday, November 6th. ValuEngine downgraded C R Bard from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Cowen reaffirmed a “hold” rating and issued a $317.00 price objective on shares of C R Bard in a research note on Friday, November 3rd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of C R Bard in a research note on Thursday, October 26th.

In other news, insider Jim C. Beasley sold 15,044 shares of the firm’s stock in a transaction on Monday, December 11th. The stock was sold at an average price of $332.00, for a total transaction of $4,994,608.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Jim C. Beasley sold 3,395 shares of the firm’s stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $332.00, for a total value of $1,127,140.00. Following the sale, the insider now owns 25,630 shares in the company, valued at approximately $8,509,160. The disclosure for this sale can be found here. Insiders have sold 32,546 shares of company stock worth $10,826,150 in the last 90 days. Insiders own 0.80% of the company’s stock.

Several hedge funds have recently bought and sold shares of the company. Candriam Luxembourg S.C.A. boosted its holdings in shares of C R Bard by 3.3% during the third quarter. Candriam Luxembourg S.C.A. now owns 4,901 shares of the medical instruments supplier’s stock worth $1,571,000 after purchasing an additional 156 shares during the last quarter. Pacer Advisors Inc. boosted its holdings in C R Bard by 10.3% in the third quarter. Pacer Advisors Inc. now owns 1,671 shares of the medical instruments supplier’s stock valued at $536,000 after acquiring an additional 156 shares during the last quarter. Monroe Bank & Trust MI boosted its holdings in C R Bard by 65.6% in the third quarter. Monroe Bank & Trust MI now owns 447 shares of the medical instruments supplier’s stock valued at $100,000 after acquiring an additional 177 shares during the last quarter. Global X MANAGEMENT CO LLC boosted its holdings in C R Bard by 11.6% in the third quarter. Global X MANAGEMENT CO LLC now owns 1,821 shares of the medical instruments supplier’s stock valued at $584,000 after acquiring an additional 189 shares during the last quarter. Finally, Amalgamated Bank boosted its holdings in C R Bard by 2.2% in the third quarter. Amalgamated Bank now owns 8,744 shares of the medical instruments supplier’s stock valued at $2,802,000 after acquiring an additional 189 shares during the last quarter. Institutional investors and hedge funds own 79.11% of the company’s stock.

The company has a debt-to-equity ratio of 0.57, a current ratio of 1.72 and a quick ratio of 1.37. The firm has a market cap of $24,140.00, a P/E ratio of 43.64, a P/E/G ratio of 2.53 and a beta of 0.52. C R Bard has a 12-month low of $223.02 and a 12-month high of $337.73.

TRADEMARK VIOLATION WARNING: This piece was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/c-r-bard-inc-bcr-receives-consensus-rating-of-hold-from-analysts/1857922.html.

C R Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Analyst Recommendations for C R Bard (NYSE:BCR)

Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.